Ustekinumab biosimilar - OncobiologicsAlternative Names: ONS-3040
Latest Information Update: 22 Oct 2015
At a glance
- Originator Oncobiologics
- Class Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Interleukin 12 subunit p40 inhibitors; Interleukin 23 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Psoriasis
Most Recent Events
- 22 Oct 2015 Preclinical trials in Psoriasis in USA (SC) prior to October 2015